Dr Woodthorpe is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a range of organizations including listed entities, government boards and for purpose organizations. She has experience working in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. Katherine also has knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Dr Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.

Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roches global organisation. He was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation.

Ms McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Ms McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands. Ms McLoughlin will also Chair of AnteoTech's Risk Committee.

Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.

Mr Crouch is currently Chairman of Corporate Travel Management Limited (ASX: CTD) and serves on the Boards of Bluescope Steel Limited (ASX: BSL) and respected Australian non-profit organisation Jawun. From 1988-2103 Mr Crouch was a partner at Allens. He served as Chairman of Partners for 4 years and held a number of practice leadership and management roles, including 11 years of service on the firm's board. He was previously a Director of Westpac Banking Corporation Limited (ASX: WBC), a director of Mission Australia including seven years as Chairman, a member of the Takeovers Panel, a member of the Commonwealth Remuneration Tribunal and a director of Sydney Symphony Orchestra. His board experience and corporate knowledge, together with his governance, legal and international transaction experience complements well the skillset of the current Board of AnteoTech.

Mr Parker has 30 years plus of experience in both domestic and international life sciences sector mainly with Roche Diagnostics ("Roche"), an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in late 2017, he was Managing Director for UK & Ireland and Management Centre for European Agents where he had responsibility for all diagnostic products in the Roche portfolio. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets. Mr Parker was a previous CEO for AnteoTech between April 2018 and May 2019 and then an Executive Director until November 2019.

-

-

-

-